CATALAYER NEWS
FDA cites severe liver injury risk, unclear benefit behind Sanofi's MS drug rejection - Fierce Biotech
Source: Fierce Biotech · 2026-01-06
Full article text is available in the Catalayer news terminal.
RELATED ON CATALAYER
Mentioned Tickers
$SNY · SanofiRELATED MARKETS
Prediction Markets